Sector News

Top 10 pharma companies by employees – 2014

October 10, 2014
Life sciences
It is probably no surprise that the 10 largest Big Pharma companies came into 2014 with far fewer employees than they had the previous year. After all, revenues have been off at those companies as some of their biggest products have fallen off the patent cliff. Thousands of jobs were lost as companies laid employees off and sold units to try to regain their balance.
 
2012 was the most severe of the patent cliff years in the decade, so it is logical that the numbers at the end of 2013, when they were last tallied up, would be significantly less than the year before. And the number? The 10 largest companies had 29,720 fewer employees at the end of last year than the previous year, a decline of about 3%. But given that revenues for those 10 were off 3.6% collectively, by some measures the downsizing was not enough. That means that revenues per employee were also lower, $493,861, based on the 2013 employment and revenue numbers, compared with $495,895 the year before.
 
Of course, not all companies shrank. Half of them–Novartis, Johnson & Johnson, Sanofi, Roche and Bayer–recorded at least some minimal growth last year. The largest of the top 10 by employees, Novartis, grew employment by 6.24% last year, adding about 8,000 employees, the largest increase in numbers and percent. But the Swiss drugmaker has been adjusting this year, with the sale of its vaccines business to GlaxoSmithKline and its animal health business to Ely Lilly, and its combo with GSK of their consumer health operations.
 
In fact, while layoffs get the most notice, spinoffs result in the most jobs lost at a company. Abbott Laboratories shed nearly 25% of its workforce in 2013, 22,000 workers, mostly because it spun off its branded pharma unit into AbbVie. Pfizer was next, losing 13,800 employees, a 15% decline. Most of that tracks back to the spinoff of its animal health business into Zoetis.
 
It is always interesting to see who is growing and who is shrinking and why, but it can be a tricky measure. A company like Pfizer can whack a big unit and see its employment picture change dramatically. A year or two later, it can buy a company, say one like AstraZeneca with 51,500 employees, and the numbers can swell once again.
 
> View the list on the Fierce Pharma website
 
By Eric Palmer
 
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach